Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Gilead Sciences, Inc. (GILD) vs GSK PLC Sponsored ADR (GSK)

Gilead Sciences, Inc. and GSK PLC Sponsored ADR are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $183.2B against $100.1B — 1.8× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; GSK PLC Sponsored ADR trades at 15.3×. GSK PLC Sponsored ADR grew revenue faster over the last twelve months: 8.72% against 5.52%. GSK PLC Sponsored ADR has the higher net margin (14.6% vs −10.6%) and the higher return on invested capital (12.6% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (4.27% vs 3.66%). Across the 22 metrics below, GSK PLC Sponsored ADR leads on 14 and Gilead Sciences, Inc. on 8.

Valuation

Metric GILD GSK Drug Manufacturers General median
P/E n/m 15.34 24.72
P/S 6.16 2.22 3.35
P/B 15.97 4.29 5.00
Price to free cash flow 14.49 12.92 17.68
EV/EBITDA 804.10 9.30 13.91
EV/Sales 6.92 2.67 3.95
Earnings yield (1.72%) 6.52% 2.92%
Free cash flow yield 6.90% 7.74% 4.42%

Profitability

Metric GILD GSK Drug Manufacturers General median
Gross margin 79.59% 72.75% 72.77%
Operating margin (8.20%) 19.55% 18.90%
Net margin (10.64%) 14.58% 8.27%
Free cash flow margin 42.50% 17.18% 17.25%
Return on equity (20.68%) 30.74% 6.97%
Return on assets (6.17%) 8.01% 2.76%
Return on invested capital (4.48%) 12.58% 6.30%

Growth

Metric GILD GSK Drug Manufacturers General median
Revenue growth (TTM) 5.52% 8.72% 6.79%
EPS growth (last fiscal year) 1,684.21% 133.96% —
Revenue growth, 5-year CAGR 3.58% (0.32%) 3.98%
Net income growth, 5-year CAGR 133.35% 0.42% 0.42%

Health

Metric GILD GSK Drug Manufacturers General median
Debt to equity 2.23 1.06 0.63
Current ratio 1.27 0.82 1.32
Net debt to EBITDA 1.35 1.39 1.15

Dividend

Metric GILD GSK Drug Manufacturers General median
Dividend yield 4.27% 3.66% 3.57%
Payout ratio 0.68 0.46 0.53

Size

Metric GILD GSK Drug Manufacturers General median
Market cap 183.22b 100.08b 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack